MDS 2025
Oct 5 - 9, 2025 | Honolulu, HI
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy ParticipantsL Smits et al.